SYNCOMF2024-10-012024-12-31 SYNCOMF2024-10-012024-12-31 SYNCOMF2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member SYNCOMF2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member SYNCOMF2024-12-31 SYNCOMF2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue01Member SYNCOMF2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue02Member SYNCOMF2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue03Member SYNCOMF2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue01Member SYNCOMF2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue02Member SYNCOMF2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue03Member SYNCOMF2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults01Member SYNCOMF2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults02Member SYNCOMF2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults03Member SYNCOMF2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults01Member SYNCOMF2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults02Member SYNCOMF2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults03Member SYNCOMF2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets01Member SYNCOMF2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets02Member SYNCOMF2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets03Member SYNCOMF2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member SYNCOMF2024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member SYNCOMF2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member SYNCOMF2024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member SYNCOMF2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities03Member SYNCOMF2024-12-31in-bse-fin:OneReportableSegmentLiabilities03Member SYNCOMF2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member SYNCOMF2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524470 SYNCOMF NOTLISTED Syncom Formulations (India) Limited Equity 2024-04-01 2025-03-31 2025-02-10 2025-02-03 INR Lakhs Third quarter 16:00:00 16:30:00 2025-02-10 2025-02-10 Not applicable Multi segment 2024-10-01 2024-12-31 Unaudited Standalone 1270292000.00 38249000.00 1308541000.00 762618000.00 71291000.00 32308000.00 139475000.00 2123000.00 13075000.00 118603000.00 1139493000.00 169048000.00 0.00 169048000.00 40282000.00 854000.00 41136000.00 0.00 127912000.00 0.00 0.00 0.00 0.00 127912000.00 1840000.00 129752000.00 0.00 0.00 940000000.00 1 0.14 0.14 0.00 0.00 0.14 0.14 0.00 0.00 0.00 Multi segment 2024-04-01 2024-12-31 Unaudited Standalone 3143860000.00 102881000.00 3246741000.00 1978688000.00 237923000.00 -150104000.00 371990000.00 7610000.00 39075000.00 345030000.00 2830212000.00 416529000.00 -24000.00 416505000.00 99514000.00 3293000.00 102807000.00 0.00 313698000.00 0.00 0.00 0.00 0.00 313698000.00 68621000.00 382319000.00 0.00 0.00 940000000.00 1 0.41 0.41 0.00 0.00 0.41 0.41 0.00 0.00 0.00 OTHER EXPENSES 118603000.00 OTHER EXPENSES 345030000.00 PHARMACEUTICALS DRUGS AND FORMULATIONS 1276627000.00 RENTING OF PROPERTY 9026000.00 TRADING OF COMMODITIES 22888000.00 PHARMACEUTICALS DRUGS AND FORMULATIONS 3157003000.00 RENTING OF PROPERTY 28499000.00 TRADING OF COMMODITIES 61239000.00 1308541000.00 3246741000.00 0.00 0.00 1308541000.00 3246741000.00 PHARMACEUTICALS DRUGS AND FORMULATIONS 162616000.00 RENTING OF PROPERTY 8218000.00 TRADING OF COMMODITIES 337000.00 PHARMACEUTICALS DRUGS AND FORMULATIONS 396421000.00 RENTING OF PROPERTY 26078000.00 TRADING OF COMMODITIES 1616000.00 171171000.00 424115000.00 2123000.00 7610000.00 0.00 1. The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 10/02/2025. 2.These above results have been prepared in compliance with the Indian Accounting Standard (referred to as Ind AS ) as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time. 3.The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required. 4.As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter/nine months ended on 31st December, 2024. The report does not have any impact on the above results and notes which needs explanation. 5.Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification. 0.00 169048000.00 416505000.00 PHARMACEUTICALS DRUGS AND FORMULATIONS 3253681000.00 RENTING OF PROPERTY 473345000.00 TRADING OF COMMODITIES 89060000.00 3816086000.00 0.00 3816086000.00 PHARMACEUTICALS DRUGS AND FORMULATIONS 546001000.00 RENTING OF PROPERTY 7748000.00 TRADING OF COMMODITIES 15500000.00 569249000.00 0.00 569249000.00 0.00 0.00 Items that will be reclassified to profit or loss 1840000.00 Items that will be reclassified to profit or loss 68621000.00 1840000.00 68621000.00 0.00 0.00